Benefits
Attention and focus
In the one trial cited here, 28 days of Cognizin brand citicoline improved attention (p=0.02) and psychomotor speed (p=0.03) versus placebo, and the higher dose predicted increased accuracy (p=0.01), improved signal detectability (p=0.03) and decreased impulsivity (p=0.01). These are real, brand-specific, placebo-controlled findings. They come from 75 healthy adolescent males in unbalanced groups of 51 and 24, and no replication in adults or in women is cited on this page.
Brain energy and membranes (mechanism, not a measured result)
Citicoline is converted to phosphatidylcholine, a major component of neuronal membranes, and it also supplies cytidine. That is a biochemical pathway rather than a measured result: the trial cited on this page did not measure brain energy, mitochondrial function, or membrane composition in any participant.
Cholinergic signaling (memory was not measured)
Citicoline supplies choline, a precursor for acetylcholine, which is the reasoning usually offered for a memory effect. The trial cited on this page did not test memory or learning at all, so this is a proposed mechanism with no supporting result here.
Mechanism of action
Dual precursor
Citicoline provides cytidine and choline, feeding both acetylcholine synthesis and the phosphatidylcholine that builds and repairs neuronal membranes.
Neuronal energy support
Citicoline's effect on mitochondrial activity is a proposed mechanism rather than a measured outcome. The one human trial cited on this page did not measure mitochondrial function, and no protective effect in people is claimed here.
Clinical trials
Randomized, placebo-controlled trial of Cognizin brand citicoline at 250 or 500 mg per day for 28 days. n=75, unevenly allocated at 51 citicoline versus 24 placebo. (McGlade et al. 2019, Journal of Attention Disorders; PMID 26179181)
75 healthy adolescent males. No adults and no women were studied. The product is sold to adults, and this trial does not speak to that population.
Attention improved (p=0.02) and psychomotor speed improved (p=0.03) versus placebo. The higher dose predicted increased accuracy (p=0.01), improved signal detectability (p=0.03) and decreased impulsivity (p=0.01). Memory was not among the measures. With one 28-day trial and unbalanced groups, this is a promising single result rather than a settled one.